December 2023 PMID 38001271

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.

Lorenzo Leggio, Christian S Hendershot, Mehdi Farokhnia, Anders Fink-Jensen, Mette Kruse Klausen, Joseph P Schacht, W Kyle Simmons

Full text PDF Download social card

Mentions

Peak: 18 in Nov 2023

across 5 sources since Nov 2023

Extended reach

42,846

potential audience

Total likes

103

Video views

3,594

Mentions per month

Nov 2023 – Feb 2025

Where it's discussed

News27 articles
X / Twitter20 posts
YouTube2 videos
Facebook2 posts
Blogs2 articles

AI synopsis

What people are saying

Discussions primarily restate the article's core message, emphasizing the promising but unproven status of GLP-1 receptor agonists for treating substance use disorders, with posts containing phrases like 'promising but unproven' and hashtags like #science and #research, indicating a neutral and informational tone that reflects cautious optimism without deep engagement or significant impact.

AgreementModerate agreement

Most discussions acknowledge that GLP-1 receptor agonists show promise but remain unproven, indicating cautious agreement with the article.

InterestModerate interest

While the topic is of some interest, the discussions mainly focus on reiterating the publication's message rather than exploring new ideas.

EngagementNeutral engagement

The engagement level is modest, with some retweets and mentions, but little deep analysis or critical discussion.

ImpactNeutral impact

The overall impact is limited as these posts underscore the preliminary nature of the research without advocating for immediate changes.

Abstract in brief

GLP1 receptor agonists show potential as treatments for alcohol and substance use disorders, but they are still in early research stages.
Current evidence from preclinical and initial human studies is promising but not conclusive for their effectiveness in treating alcohol use disorder.
Until more research confirms their safety and effectiveness, approved treatments should continue to be used for managing alcohol and substance use disorders.]

Read the full abstract

All mentions

GLP-1 Receptor Agonists for Cardiovascular and Substance Use Disorders

Dr. Michael Lincoff discusses the SELECT study testing semaglutide for cardiovascular risk reduction in non-diabetic overweight or obese patients, highlighting experimental findings and clinical implications.

MARKUS at HOMe · Feb 2, 2024 1,922 views

Tirzepatide for HFPEF and Obesity: SUMMIT Trial Insights

Professor Barry Borlaug discusses the SUMMIT trial on GIP GLP1 receptor dual agonist use in obesity-related HeartFailure with Preserved Ejection Fraction, published in NEJM 2024, highlighting potential new treatments…

MARKUS at HOMe · Feb 14, 2025 1,673 views

SergeAhmed

@SergeAhmed · X

Important caution: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/R6dxchwhzL

Dec 20, 2023 · 3,959 followers View post →

HealthyBuilds

@JamesSw70043542 · X

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/P7UtjiVNm1

Dec 14, 2023 · 18 followers View post →

Life Science Journal Content

@lsn_jc · X

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders #science #publication #research #journal https://t.co/OoP3geZ26t

Nov 26, 2023 · 261 followers View post →

安息

@ngwcp7 · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 26, 2023 · 9 shares · 2,700 followers View post →

Ranganath Muniyappa

@dr_muniyappa · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 25, 2023 · 9 shares · 1,089 followers View post →

Filip K. Knop

@Filip_Knop · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 25, 2023 · 9 shares · 2,514 followers View post →

Yanina Pepino

@YaniPepino · X

RT @MehdiFarokhnia:

Nov 25, 2023 · 6 shares · 214 followers View post →

Prof. Chris Langmead

@chrislangmead · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 25, 2023 · 9 shares · 1,937 followers View post →

Abstream

@abstreamme · X

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders #science #publication #research #publications https://t.co/Aii3srvGiv

Nov 25, 2023 · 786 followers View post →

..OhISeeYou'D!!

@oiccud · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 25, 2023 · 9 shares · 182 followers View post →

Ginevra D'Ottavio

@ginevradottavio · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 25, 2023 · 9 shares · 542 followers View post →

Harpreet Kaur

@Hkaur_p · X

RT @MehdiFarokhnia:

Nov 25, 2023 · 6 shares · 298 followers View post →

NARC

@bic_ismms · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 24, 2023 · 9 shares · 611 followers View post →

Leah Mayo

@MayoOnTheBrain · X

RT @Lorenzo__Leggio: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9…

Nov 24, 2023 · 9 shares · 2,839 followers View post →

Lorenzo Leggio

@Lorenzo__Leggio · X

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders https://t.co/ra9BuAm3JY

Nov 24, 2023 · 26 likes · 9 shares · 1,072 followers View post →

Leah Mayo

@MayoOnTheBrain · X

RT @MehdiFarokhnia:

Nov 24, 2023 · 6 shares · 2,839 followers View post →

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat · X

RT @MehdiFarokhnia:

Nov 24, 2023 · 6 shares · 3,348 followers View post →

Brianna George, PhD

@BriannaEGeorge · X

RT @MehdiFarokhnia:

Nov 24, 2023 · 6 shares · 1,340 followers View post →

Jibran Khokhar

@DrJKhokhar · X

RT @MehdiFarokhnia:

Nov 24, 2023 · 6 shares · 10,819 followers View post →

Mehdi Farokhnia مهدی فرخ‌نیا

@MehdiFarokhnia · X

Nov 24, 2023 · 25 likes · 6 shares · 1,639 followers View post →

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

GLP-1 Receptor Agonists for Cardiovascular and Substance Use Disorders

Tirzepatide for HFPEF and Obesity: SUMMIT Trial Insights